RBC Capital analyst Alistair Campbell maintained a Buy rating on Pharming Group (PHGUF – Research Report) on November 7 and set a price target of €1.95. The company’s shares closed last Monday at $1.14.
According to TipRanks, Campbell is ranked #1639 out of 8489 analysts.
Currently, the analyst consensus on Pharming Group is a Moderate Buy with an average price target of $2.11, an 85.09% upside from current levels. In a report released on October 27, Stifel Nicolaus also maintained a Buy rating on the stock with a €2.05 price target.
See the top stocks recommended by analysts >>
PHGUF market cap is currently $795.9M and has a P/E ratio of -35.42.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pharming Group (PHGUF) Company Description:
Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company offers RUCONEST which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following geographical segments: the United States, Europe, and Rest of the World. The company was founded on November 11, 1988 and is headquartered in Leiden, the Netherlands.
